Axogen, Inc. (AXGN): Price and Financial Metrics
AXGN Price/Volume Stats
Current price | $7.71 | 52-week high | $10.83 |
Prev. close | $7.68 | 52-week low | $3.45 |
Day low | $7.50 | Volume | 360,500 |
Day high | $7.88 | Avg. volume | 464,562 |
50-day MA | $9.29 | Dividend yield | N/A |
200-day MA | $7.32 | Market Cap | 333.12M |
AXGN Stock Price Chart Interactive Chart >
AXGN POWR Grades
- AXGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.26% of US stocks.
- The strongest trend for AXGN is in Stability, which has been heading down over the past 26 weeks.
- AXGN ranks lowest in Momentum; there it ranks in the 4th percentile.
AXGN Stock Summary
- AXGN has a market capitalization of $285,379,108 -- more than approximately 31.16% of US stocks.
- AXOGEN INC's stock had its IPO on March 27, 1990, making it an older stock than 84.83% of US equities in our set.
- In terms of volatility of its share price, AXGN is more volatile than 82.57% of stocks we're observing.
- Stocks that are quantitatively similar to AXGN, based on their financial statements, market capitalization, and price volatility, are WRAP, REFR, ECOR, ASPN, and HEAR.
- Visit AXGN's SEC page to see the company's official filings. To visit the company's web site, go to www.axogeninc.com.
AXGN Valuation Summary
- AXGN's price/earnings ratio is -12.7; this is 143.57% lower than that of the median Healthcare stock.
- AXGN's price/earnings ratio has moved down 10.9 over the prior 243 months.
Below are key valuation metrics over time for AXGN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AXGN | 2023-12-29 | 1.9 | 3.0 | -12.7 | -14.7 |
AXGN | 2023-12-28 | 1.9 | 3.0 | -12.7 | -14.8 |
AXGN | 2023-12-27 | 2.0 | 3.1 | -12.9 | -15.0 |
AXGN | 2023-12-26 | 2.0 | 3.1 | -13.2 | -15.3 |
AXGN | 2023-12-22 | 2.0 | 3.1 | -13.0 | -15.1 |
AXGN | 2023-12-21 | 2.0 | 3.1 | -13.2 | -15.3 |
AXGN Growth Metrics
- Its 3 year cash and equivalents growth rate is now at -29.51%.
- The 4 year net income to common stockholders growth rate now stands at -91.93%.
- Its 4 year cash and equivalents growth rate is now at 61.67%.
The table below shows AXGN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 133.957 | -18.942 | -28.819 |
2022-06-30 | 128.202 | -18.629 | -31.642 |
2022-03-31 | 127.328 | -13.636 | -31.8 |
2021-12-31 | 127.358 | -13.405 | -26.985 |
2021-09-30 | 128.316 | -9.054 | -27.709 |
2021-06-30 | 130.54 | -6.06 | -22.047 |
AXGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AXGN has a Quality Grade of C, ranking ahead of 50.98% of graded US stocks.
- AXGN's asset turnover comes in at 0.65 -- ranking 58th of 186 Medical Equipment stocks.
- ADMT, NDRA, and APYX are the stocks whose asset turnover ratios are most correlated with AXGN.
The table below shows AXGN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.650 | 0.821 | -0.111 |
2021-03-31 | 0.625 | 0.816 | -0.133 |
2020-12-31 | 0.633 | 0.808 | -0.172 |
2020-09-30 | 0.651 | 0.806 | -0.219 |
2020-06-30 | 0.661 | 0.808 | -0.294 |
2020-03-31 | 0.706 | 0.829 | -0.278 |
AXGN Price Target
For more insight on analysts targets of AXGN, see our AXGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $27.00 | Average Broker Recommendation | 1.43 (Moderate Buy) |
Axogen, Inc. (AXGN) Company Bio
AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.
Latest AXGN News From Around the Web
Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.
Axogen, Inc. Appoints Kathy Weiler to its Board of DirectorsWeiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven |
Axogen Announces Transition of Finance Team LeadershipNir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of GrowthALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience |
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations. Mr. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will |
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare ConferenceALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T. Webcast events can be accessed live through the Investors page at www.axogeninc.com. F |
Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous yearKey Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the... |
AXGN Price Returns
1-mo | -27.26% |
3-mo | 9.21% |
6-mo | 48.27% |
1-year | -6.20% |
3-year | -64.09% |
5-year | -62.41% |
YTD | 12.88% |
2023 | -31.56% |
2022 | 6.51% |
2021 | -47.65% |
2020 | 0.06% |
2019 | -12.43% |
Continue Researching AXGN
Want to do more research on Axogen Inc's stock and its price? Try the links below:Axogen Inc (AXGN) Stock Price | Nasdaq
Axogen Inc (AXGN) Stock Quote, History and News - Yahoo Finance
Axogen Inc (AXGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...